ERBB2 and breast cancer: While both cell lines were derived from aggressive HER2+ breast cancers, the treatment protocols each patient received likely contributed to the overall behavior of the resultant cell lines in culture beyond the obvious sensitivity or resistance to HER2 inhibitors.